Literature DB >> 15071042

Dissemination of a clone of unusual phenotype of pandrug-resistant Acinetobacter baumannii at a university hospital in Taiwan.

Lu-Cheng Kuo1, Lee-Jene Teng, Chong-Jen Yu, Shen-Wu Ho, Po-Ren Hsueh.   

Abstract

From December 2002 to February 2003, 15 isolates of pandrug-resistant unidentified Acinetobacter species were recovered from seven patients treated on different wards or intensive care units. Both 16S-23S rRNA intergenic spacer PCR-restriction fragment length polymorphism profiles and sequence analysis of these isolates identified them as Acinetobacter baumannii. This pandrug-resistant A. baumannii strain with an unusual phenotype could persist in humans for long periods and was widely disseminated throughout the hospital.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15071042      PMCID: PMC387598          DOI: 10.1128/JCM.42.4.1759-1763.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Resistance to antibiotics and biocides among non-fermenting Gram-negative bacteria.

Authors:  C S Higgins; S M Murtough; E Williamson; S J Hiom; D J Payne; A D Russell; T R Walsh
Journal:  Clin Microbiol Infect       Date:  2001-06       Impact factor: 8.067

2.  Multicenter surveillance of antimicrobial resistance of major bacterial pathogens in intensive care units in 2000 in Taiwan.

Authors:  P R Hsueh; Y C Liu; D Yang; J J Yan; T L Wu; W K Huang; J J Wu; W C Ko; H S Leu; C R Yu; K T Luh
Journal:  Microb Drug Resist       Date:  2001       Impact factor: 3.431

3.  Comparative in vitro antimicrobial susceptibilities of nosocomial isolates of Acinetobacter baumannii and synergistic activities of nine antimicrobial combinations.

Authors:  M B Marques; E S Brookings; S A Moser; P B Sonke; K B Waites
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features.

Authors:  J M Cisneros; M J Reyes; J Pachón; B Becerril; F J Caballero; J L García-Garmendía; C Ortiz; A R Cobacho
Journal:  Clin Infect Dis       Date:  1996-06       Impact factor: 9.079

5.  MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections.

Authors: 
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

6.  Identification of Acinetobacter isolates in the A. calcoaceticus-A. baumannii complex by restriction analysis of the 16S-23S rRNA intergenic-spacer sequences.

Authors:  L Dolzani; E Tonin; C Lagatolla; L Prandin; C Monti-Bragadin
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

7.  Clinical and epidemiological investigations of Acinetobacter genomospecies 3 in a neonatal intensive care unit.

Authors:  A Horrevorts; K Bergman; L Kollée; I Breuker; I Tjernberg; L Dijkshoorn
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

8.  Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam.

Authors:  Anna S Levin; Carlos E Levy; A Edison I Manrique; Eduardo A S Medeiros; Silvia F Costa
Journal:  Int J Antimicrob Agents       Date:  2003-01       Impact factor: 5.283

9.  Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Cheng-Yi Chen; Wen-Hwei Chen; Chong-Jen Yu; Shen-Wu Ho; Kwen-Tay Luh
Journal:  Emerg Infect Dis       Date:  2002-08       Impact factor: 6.883

10.  Current status of antimicrobial resistance in Taiwan.

Authors:  Po-Ren Hsueh; Cheng-Yi Liu; Kwen-Tay Luh
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

View more
  10 in total

1.  Infection Associated with Hemophagocytic Lymphohisticytosis triggered by nosocomial Infection.

Authors:  J B Gosh; Mahua Roy; Ashok Bala
Journal:  Oman Med J       Date:  2009-07

2.  Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline.

Authors:  F S Taccone; H Rodriguez-Villalobos; D De Backer; V De Moor; J Deviere; J-L Vincent; F Jacobs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-04       Impact factor: 3.267

3.  Geographical patterns in antimicrobial resistance of acinetobacter in clinical isolates.

Authors:  Naz Perween; Sonal Sehgal; S Krishna Prakash
Journal:  J Clin Diagn Res       Date:  2014-04-15

4.  Proteomic analysis of outer membrane proteins from Acinetobacter baumannii DU202 in tetracycline stress condition.

Authors:  Sung-Ho Yun; Chi-Won Choi; Soon-Ho Park; Je Chul Lee; Sun-Hee Leem; Jong-Soon Choi; Soohyun Kim; Seung Il Kim
Journal:  J Microbiol       Date:  2008-12-24       Impact factor: 3.422

5.  Homeostasis of glutathione is associated with polyamine-mediated β-lactam susceptibility in Acinetobacter baumannii ATCC 19606.

Authors:  Dong H Kwon; Saboor Hekmaty; Gomattie Seecoomar
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

6.  Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance.

Authors:  Kyungwon Lee; Ki Hyung Park; Seok Hoon Jeong; Hwan Sub Lim; Jong Hee Shin; Dongeun Yong; Gyoung-Yim Ha; Yunsop Chong
Journal:  Yonsei Med J       Date:  2006-02-28       Impact factor: 2.759

7.  Resistant mechanisms and molecular epidemiology of imipenem-resistant Acinetobacter baumannii.

Authors:  Shu-Zhen Xiao; Hai-Qing Chu; Li-Zhong Han; Zhe-Min Zhang; Bing Li; Lan Zhao; Liyun Xu
Journal:  Mol Med Rep       Date:  2016-07-22       Impact factor: 2.952

Review 8.  How Phages Overcome the Challenges of Drug Resistant Bacteria in Clinical Infections.

Authors:  Majid Taati Moghadam; Nour Amirmozafari; Aref Shariati; Masoumeh Hallajzadeh; Shiva Mirkalantari; Amin Khoshbayan; Faramarz Masjedian Jazi
Journal:  Infect Drug Resist       Date:  2020-01-07       Impact factor: 4.003

9.  Treatment of Staphylococcus aureus skin infection in vivo using rifampicin loaded lipid nanoparticles.

Authors:  Anna Walduck; Parveen Sangwan; Quynh Anh Vo; Julian Ratcliffe; Jacinta White; Benjamin W Muir; Nhiem Tran
Journal:  RSC Adv       Date:  2020-09-11       Impact factor: 4.036

Review 10.  Infections Caused by Acinetobacter baumannii in Recipients of Hematopoietic Stem Cell Transplantation.

Authors:  Khalid Ahmed Al-Anazi; Asma M Al-Jasser
Journal:  Front Oncol       Date:  2014-07-14       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.